All News

Can These Stocks Double in Value, and Still be 70% off Their Recent High? Read More and Decide. Point #1. We've been playing turnaround situations...

In an era of rapid scientific development, the pharmaceutical industry constantly evolves to meet new challenges and seize emerging opportunities. GeoVax, a biotechnology company...

We think there is a potential Tsunami of business headed towards Pressure Bio over then next 3-5 years. And well beyond. As the chart...

Initiating Coverage on Psycheceutical BioScience (BWVI). "Imagine Applying a Psychedelic Topically, Receiving the Benefits Quicker Than Alternative Delivery Methods (Injection, Intravenously, Nasally or Orally) and...

We Think it is! Webinar to discuss effectiveness. The Company does not make CBD Oil, it makes any CBD Oil better. Press release out today about their...

Cohen Psychedelic Research & Health Initiative Cohen Foundation Awards $5 Million for MDMA Therapy Approval Millions of Americans suffer from depression, anxiety, addiction, post-traumatic stress disorder...

Scientists pinpoint location of plaque ruptures, and a protein that predicts them (FierceBio) Scientists have uncovered new details about the mechanisms that cause plaques...

Completion of Enrollment Remains on Track for Q1, 2024 "While we recently had fireworks, we could be looking at real fireworks in the coming year....

Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests NeuroDirect™ Ketamine....

Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD. Company raises $1.3M USD convertible note from Cantheon Capital for in-human trials...